Question One: What are the potential investment risks involved with interest rate securities? Interest rate securities can be traded on the ASX‚ e.g. floating rate notes‚ convertible notes‚ and hybrid debt securities. This type of security is a form of bond which pays a coupon payment‚ either fixed or floating‚ plus it pays the face value upon maturity. The main risk associated with these securities is that the coupon payment (cash flow) is fixed for the life of the security unless it is a
Premium Bond Debt Finance
PHARMA-SAYA INNOVATIVE SOLUTIONS‚ INC. Bringing better smiles that build better lives 259 CEU Bldg.‚ Sen. Gil Puyat Ave.‚ Makati City Phils. OUR MOTTO Bringing better smiles that build better lives. OUR MISSION-VISION STATEMENT PSIS is a Philippine company that values one of the most cognizant traits of the Filipino men‚ being gleeful‚ where the connotation that the SMILE is the most powerful weapon and shield of the Filipino started. The company is dedicated to bring better
Free Metro Manila Manila Toothpaste
REPORT 2009-10 Torrent Pharmaceuticals Limited 2 N TE CO N TS Corporate Information 02 Notice 03 Directors’ Report 06 Report on Corporate Governance 14 Auditors’ Report 24 Audited Financial Statements 28 Management Discussion and Analysis 55 Consolidated Financial Statements 66 37th ANNUAL REPORT 2009-10 3 CORPORATE INFORMATION DIRECTORS Sudhir Mehta Chairman REGISTERED OFFICE Torrent House‚ Markand Bhatt S. H. Bhojani Dr. Prasanna Chandra Kiran Karnik Sanjay Lalbhai
Premium Board of directors Corporate governance
Bio Pharma Case Analysis Question 1 How should BioPharma have used its production network in 2009? Should any of the plants have been idled? What is the annual cost of your proposal‚ including import duties? As Landgraf’s objective is to design a more cost-effective network (cost minimization problem subject to various capacity constraints)‚ the following production network in 2009 should have been used by BioPharma: *All numbers below are in millions *Total Transportation Cost=SUMPRODUCT
Premium Costs Total cost Variable cost
01.Retern on capital employed (ROCE) (Return/Capital employed) × 100 2007 2008 2009 Return 654420059 963775308 1156895419 Capital employed 2941937693 13932986985 13512352515 ROCE 5.85% 4.99% 8.56% Table: ROCE 02.Return on shareholders’ fund (ROSF) {Net profit for the period/(Share capital+Reserve)} 2007 2008 2009 Net profit for the period 3597024812 4010167059 4868256915 Share capital+Reserve 1932104953 1554528420 1806443640 ROSF 1.86 2.58 2.69 Table: ROSF
Premium Financial ratios Generally Accepted Accounting Principles Financial ratio
Financial Analysis: [pic] Submitted To: Dr. Masud Rahman Submitted By: Nogmaye Habiba ID # 073293060 Mehrin Afroze Chowdhury ID # 072 475 060 M. Rubbyat Akram ID # 063085060 Submission Date: 12th April‚ 2009 [pic] April 12‚ 2009 To‚ Dr. Masud Rahman Professor‚ MBA Program North South University Dear Sir‚
Premium Balance sheet Stock market Stock
Introduction: BEXIMCO Pharmaceuticals Limited’ belongs to BEXIMCO Group‚ the largest private sector industrial conglomerate in Bangladesh. Over the last thirty years the company was making good profit. In this paper‚ the last two years financial statement of BEXIMCO Pharmaceuticals Limited has been analyzed.. Company Profile of ‘BEXIMCO Pharmaceuticals Limited’: BEXIMCO Pharmaceuticals Ltd. (BPL) is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs)
Premium Balance sheet Financial ratio Financial ratios
1) Millenniums Pharmaceuticals strategy basically focused on revolutionizing drug development through the use of new technology during growth phase and making organizational changes during its maturing phase of by making strategic improvements in the organizational structure‚ making alliances‚ outsourcing etc by having vertical integration and moving from upstream to downstream model. In phase 1‚ technology helped the firm leapfrog most other biotechnology firms in the early stage of drug target
Premium Strategic management
Birmingham‚ November 2011 Nico Bacharidis Globally‚ Tenders & Contracts cover more than half of the Gx market‚ and also affect around 14% of the patented pharma market . In Mature markets the share of tenders - both patented and protected – is a bit lower. •Estimated Size1) of Tendered and Contracted Pharma Market ($bn) •27% of total pharma •$210bn 767 160 Tendered Contracted 141 Generics Total Gx Mar ket •Tendered and Contracted Market by Gx and Patented ($bn) 210 •Over 50% of the global
Premium European Union United Kingdom Western Europe
FUNDAMENTAL ANALYSIS ON MARUTI SUZUKI LIMITED SUBMITTED BY GHOUSE BAIG 6 B.COM C 08D0237 COMPANY PROFILE Maruti Suzuki India Limited (MSIL) is a passenger car company. The Company is engaged in the business of manufacturing‚ purchase and sale of motor vehicles and spare parts (automobiles). The other activities of the Company include facilitation of pre-owned car sales‚ fleet management and car financing. The Company is a subsidiary of Suzuki Motor Corporation‚ Japan. The Company
Premium Financial ratios Maruti Suzuki Suzuki